Silver Book Fact

After 54 weeks of receiving bevacizumab, wet age-realted macular degeneration (AMD) patients were more likely to gain at least 6 letters of contrast sensitivity than patikents recieving standard care–35.4% versus 15.2%.

Patel, J. Praveen, Fred K. Chen, Lyndon Da Cruz, Gary S. Rubin, Adnan Rufail; for the ABC Trial Study Group. Contrast Sensitivity Outcomes in the ABC Trial: A Randomized Trial of Bevacizumab for Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. February 2011; 52(6): 3089-93. http://www.iovs.org/content/early/2011/02/09/iovs.10-6208.full.pdf

Reference

Title
Contrast Sensitivity Outcomes in the ABC Trial: A Randomized Trial of Bevacizumab for Neovascular Age-Related Macular Degeneration
Publication
Invest Ophthalmol Vis Sci
Publication Date
February 2011
Authors
Patel, J. Praveen, Fred K. Chen, Lyndon Da Cruz, Gary S. Rubin, Adnan Rufail; for the ABC Trial Study Group
Volume & Issue
Volume 52, Issue 6
Pages
3089-93
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Laser treatment and vitrectomy reduce the risk of blindness in patients with severe diabetic retinopathy by 90%.  
  • AMD risk reduction through diet
    A recent study indicated that 20% of AMD cases in the AREDS study would have been eliminated if the participants consumed diets with a dGI (dietary glycemic index) below the…  
  • Current treatments for proliferative diabetic retinopathy have reduced the rate of blindness within 5 years from 50% to less than 5%.  
  • Increase in AMD risk for people with a high dGI
    A recent study showed that there was a 49% increase in the risk of advanced AMD for people with a dGI (dietary glycemic index) higher than the sex median (women…  
  • Tele-ophthalmology
    Adequately trained general practitioners can screen for DR with 90% sensitivity using tele-ophthalmology.